Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database
TMP-SMX may increase the risk of ARF/ARDS, requiring further validation in larger pharmacoepidemiological studies. Our findings lay the groundwork for future research to further investigate the safety profile of TMP-SMX in adolescent populations. If confirmed, prescribers should exercise greater caution when prescribing TMP-SMX to adolescents and young adults.
Authors
- Eric McArthur (ORCID: https://orcid.org/0009-0000-6944-6471)
- Sheikh Shaugat Abdullah (ORCID: https://orcid.org/0000-0003-2452-8494)
- Facundo García‐Bournissen (ORCID: https://orcid.org/0000-0002-8732-247X)
- Flory Tsobo Muanda (ORCID: https://orcid.org/0000-0003-4682-6564)
- Fatemeh Ahmadi (ORCID: https://orcid.org/0000-0001-5425-4557)
- Mohammad Ali Omrani (ORCID: https://orcid.org/0000-0001-6847-0699)
- Niaz Chalabianloo
Institutions
- Western University (CA)
- Lawson Health Research Institute (CA)
- London Health Sciences Centre (CA)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1177/10600280251320690
- Citations
- 4
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 5.23